Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that researchers are scheduled to present data from clinical studies of Soliris
(eculizumab) in patients with atypical hemolytic uremic syndrome (aHUS) and Shiga toxin-producing
hemolytic uremic syndrome (STEC-HUS), two severe and life-threatening ultra-rare disorders caused by uncontrolled complement activation, at the annual meeting of the American Society of Nephrology (ASN). Abstracts summarizing these presentations were published today on the ASN website and can be accessed using the links below. The ASN annual meeting will be held October 30 – November 4, 2012 in San Diego, California.
Soliris is approved in the US, European Union, Japan and other countries as the first and only treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), a debilitating, ultra-rare and life-threatening blood disorder, characterized by complement-mediated hemolysis (destruction of red blood cells). Soliris is also approved in the United States as the first and only treatment for patients with atypical hemolytic uremic syndrome (aHUS), a debilitating, ultra-rare, life-threatening and chronic genetic disorder characterized by complement-mediated thrombotic microangiopathy (blood clots in small vessels). Soliris is not indicated for the treatment of patients with Shiga toxin-producing
hemolytic uremic syndrome (STEC-HUS).
Soliris and aHUS
The following abstract will be presented in a poster presentation on Thursday, November 1, 2012 from 10:00 a.m. – 12:00 p.m., Pacific Daylight Time (PDT):
Abstract TH-PO442: “Eculizumab Is Effective in Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Regardless of Underlying Genetic Mutations or Complement Factor H (CFH) Auto-Antibodies,” Goodship, et al.
The following abstract will be presented in a poster session on Saturday, November 3, 2012 from 10:00 a.m. – 12:00 p.m., PDT:
Abstract SA-PO1039: “Eculizumab Therapy in an Atypical Hemolytic Uremic Syndrome (aHUS) Patient with Long-Term Renal Failure and Posterior Reversible Encephalopathy Syndrome (PRES),” Povey, et al.